We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Diagnostic Biomarker Predicts Risk of Opisthorchiasis Cholangiocarcinoma

By LabMedica International staff writers
Posted on 10 Mar 2022
Print article
Image: Opisthorchiasis-associated cholangiocarcinoma. (A) Cholangiocarcinoma specimen showing adult worms in the bile duct (blue arrows). (B) Adult Opisthorchis viverrini recovered from the liver (Photo courtesy of Khon Kaen University)
Image: Opisthorchiasis-associated cholangiocarcinoma. (A) Cholangiocarcinoma specimen showing adult worms in the bile duct (blue arrows). (B) Adult Opisthorchis viverrini recovered from the liver (Photo courtesy of Khon Kaen University)

Opisthorchiasis is caused by an infection with fish-borne liver flukes of the genus Opisthorchis. Opisthorchiasis frequently leads to chronic inflammation in the biliary tract and is classified as a group 1 biological carcinogen by the International Agency for Research on Cancer as a definitive risk for cholangiocarcinoma (CCA).

Opisthorchiasis infection is considered heavy when there are 10,000-30,000 eggs in one gram of feces. Symptoms of heavier infections with Opisthorchis viverrini may include: diarrhea, epigastric and upper right quadrant pain, lack of appetite (anorexia), fatigue, yellowing of the eyes and skin (jaundice) and mild fever.

Parasitologists at the Khon Kaen University (Khon Kaen, Thailand) included in a study 103 serum samples. These sera were assigned to three groups as follows: group I, CCA group (n = 36); group II, other cancers and liver cirrhosis group (n = 47) including hepatocellular carcinoma (n = 28), liver cirrhosis (n = 4), colorectal cancer (n = 8), and brain cancer (n = 7); and group III, other healthy individuals (n = 20). The scientists used the rapid immunochromatographic test (ICT) to detect anti-Opisthorchis viverrini IgG and IgG4 subclass antibodies in sera of patients with CCA. The ICT kits were developed based on soluble antigens excreted and secreted by O. viverrini adult worms.

The investigators reported that ICT indicated sera was positive for IgG and IgG4 antibodies, respectively, in 22 (61.1%) and 15 (41.6%) participants of the 36 study participants diagnosed with CCA. The study also included groups with other cancers and with liver cirrhosis, where the IgG ICT and IgG4 ICT kits were 27.7% (13/47) and 25.5% (12/47) positive, respectively. Neither total the IgG ICT nor the IgG4 ICT yielded positive results in a control group of 20 healthy participants. Moreover, the percentage positivity rate using the ICT for total IgG between the CCA group and the other cancers and liver cirrhosis group was significantly different. By contrast, no significant difference between these groups was apparent in the ICT for IgG4 antibody. The CCA group was 6.53 times more likely to have positive anti–O. viverrini IgG antibody (odds ratio 6.53) and 3.27 times more likely to have positive anti–O. viverrini IgG4 antibody (odds ratio 3.27) than the non-CCA group.

The authors concluded that these findings highlighted the diagnostic potential of a rapid ICT platform that uses ES products from O. viverrini flukes for serodiagnosis of opisthorchiasis-associated CCA. The study was published on March 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
Khon Kaen University 

Gold Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette
SARS-CoV-2 IgG Antibodies Anti-S1 Assay
iRapid SARS-CoV-2 Quant "Neutralizing" Ab
Automated R-AST Solution
Radian BC
Molecular Diagnostic System
FlashDetect Flash48

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.